What Highlight Capital does

Highlight Capital (弘晖基金, HLC) is a Shanghai-headquartered Chinese venture capital and private equity firm founded in 2014, operating dual-currency fund vehicles across the RMB and USD (HLC USD Fund) denominations. The firm focuses on two primary investment verticals: Healthcare & Life Sciences (covering frontier biotechnology, innovative drugs, medical devices, diagnostics, CRO/CDMO services, gene and cell therapies, and precision medicine) and Technology & Manufacturing (semiconductors, advanced manufacturing, new materials, AI, and embodied AI/humanoid robotics). As of late 2025, the firm has invested in 200+ portfolio companies, achieved 30+ IPOs across HKEX, Nasdaq, STAR Market, and BSE, and reports 12 years of equity investment and fund management experience. Headcount is reported at 11-50 employees, with offices in Shanghai (headquarters), Beijing, Shenzhen, Nanjing, and Chongqing.

HLC's business model is that of a traditional PE/VC fund manager: it earns recurring management fees across multiple fund vehicles (RMB growth fund, USD fund, Chongqing biomedical QFLP fund, Chongqing New Quality Productivity Fund, Nanjing Angel Fund) and performance-based carried interest and equity gains from exits. The 2025-2026 exit track record includes the $1.5B acquisition of portfolio company Arthrosi Therapeutics, a $570M Medilink-Roche licensing deal, the $800M+ Avenzo transaction, and multiple FDA approvals and global pharma licensing deals (GSK $500M+, Merck-Lilly up to $910M). Notable investees span Mindray, Tigermed, United Imaging, Pharmaron, Yuwell, Sansure, Smoore International, WuXi AppTec, and Spirit AI (a unicorn in embodied AI). The firm's competitive positioning rests on a research-driven investment framework grounded in chemistry, biology, materials engineering, electronics, and mechanical engineering, combined with a system-level post-investment empowerment model that channels capital, strategic guidance, and ecosystem introductions to portfolio companies.

Distribution and deal flow operate through three reinforcing channels: direct field-based sourcing by investment teams in Shanghai, Beijing, and Shenzhen; event- and community-led ecosystem development via the HLC Family network (200+ portfolio companies), industry conferences, and cross-border activity weeks in Korea, Japan, and Southeast Asia; and government/district partnerships including Chongqing International Bio-city, Wuxi Huishan, Huangpu Central Sci-Innovation Zone, and Seoul Metropolitan Government. Marketing is anchored on WeChat official accounts (HLC Family and HLC Event branded channels) and a corporate news portal, supplemented by analyst recognitions such as Zero2IPO China VC Top 25 and Healthcare Investment Institution Top 30 (2025). Leadership includes Founder & CEO Steven Wang and Founding Partner Zhao Gang, with VP Alvin Yan and Director Pascal-Christian Sarana.

Name

Highlight Capital

Legal name

弘晖基金

Website

https://hlc.com.cn

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Highlight Capital (弘晖基金/HLC) is a Shanghai-headquartered Chinese venture capital and private equity firm founded in 2014, investing across healthcare/life sciences and technology/manufacturing via RMB and USD fund vehicles. It serves early- and growth-stage Chinese companies with a 200+ portfolio and 30+ IPO track record.

Ownership category

akta.pro rank

Product category

Private Equity and Venture Capital Fund Management

NAICS

Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Thematic / Sector-Focused Multi-Manager Platforms (FSANAGAH)

Keywords

• Venture capital
• Private equity
• Healthcare investment
• Fund management
• Growth equity

Headquarters

HQ city

Nanjin

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Fund management fees: Recurring management fees earned across multiple RMB and USD vehicles, including RMB growth funds, USD funds (HLC USD fund), regional thematic funds (e.g., Chongqing New Quality Productivity Fund, Chongqing biomed QFLP fund, Nanjing Angel Fund), and angel-stage funds. These fees form the recurring revenue base of the fund management business.
2. Carried interest and investment returns from exits: Performance-based carried interest and equity gains from successful portfolio exits. Demonstrated by 30+ IPOs of portfolio companies and major exits such as the $1.5B acquisition of Arthrosi Therapeutics, $950M acquisition of Promis Biologics (普米斯), $800M+ Avenzo deal, multiple FDA approvals, and licensing deals (Roche $570M, GSK $500M+, Merck-Lilly up to $910M). Returns are realized through IPO listings (HKEX, Nasdaq, STAR Market, BSE), M&A, and strategic licensing transactions.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Highlight Capital (弘晖基金/HLC) is a private venture capital and private equity fund management firm that invests in early- and growth-stage Chinese companies across two flagship verticals: Healthcare & Life Sciences (biotech, innovative drugs, medical devices, diagnostics, CRO/CDMO) and Technology & Manufacturing (semiconductors, advanced manufacturing, new materials, AI, embodied AI/robotics). Capital is deployed through a family of complementary fund vehicles including RMB growth funds, the HLC USD Fund, the Chongqing Biomedical QFLP Fund, the HLC Chongqing New Quality Productivity Fund, and the HLC Nanjing Angel Fund, with system-level post-investment empowerment services to portfolio companies.

Product overview

Highlight Capital (弘晖基金 / HLC) is a single integrated venture capital and private equity firm rather than a platform-plus-modules product architecture. Its core offerings are organized around two flagship investment verticals — Healthcare (医疗健康) and Technology & Manufacturing (科技制造) — executed through a family of complementary fund vehicles including the RMB-denominated primary fund, the 弘晖(HLC)美元基金 (USD Fund), the regional 弘晖新质生产力重庆基金 (Chongqing New Quality Productivity Fund) and 弘晖南京天使基金 (Nanjing Angel Fund), and the specialized Chongqing Biomedical QFLP Fund. Together, the Healthcare and Technology & Manufacturing verticals define the investment thesis, while the named fund vehicles enable execution across geographies (Shanghai HQ with Beijing and Shenzhen offices), stages (early/growth), and currencies (RMB and USD). The firm invests independently based on deep research in chemistry, biology, materials science, electronics, and mechanical engineering, and provides systematic post-investment empowerment services to portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare Investment Line (医疗健康)
• Technology & Manufacturing Investment Line (科技制造)
• HLC USD Fund (弘晖(HLC)美元基金)

Quantifiable outcome

• 30+ portfolio company IPOs across HKEX, Nasdaq, STAR Market, and BSE
• +6 more outcomes

Named customers20 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered moderate, flagship and minor.

• Seoul Metropolitan Government (首尔市)moderateStrategic or Co-development Partner · 1 December 2025HLC signed a cooperation agreement with the Seoul Metropolitan Government in 2025-12 to open a new chapter in China-Korea biomed cooperation. This was reinforced by HLC's invitation to the Korean President's China visit event on 2026-01-07. The partnership enables HLC portfolio companies' access to Korean biomed ecosystem, clinical partnerships, and cross-border deal flow.
• Zhejiang University (浙江大学)moderateStrategic or Co-development Partner · 1 July 2025Pharmaron (康龙化成), an HLC portfolio company, signed a comprehensive strategic cooperation agreement with Zhejiang University on 2025-07-11. HLC supports and amplifies portfolio-company partnerships of this kind.
• Chongqing International Bio-city (重庆国际生物城)flagshipStrategic or Co-development Partner · 1 April 2025HLC established Chongqing's first biomed QFLP fund (Qualified Foreign Limited Partnership fund) within the Chongqing International Bio-city in 2025-04. This was followed by the establishment of the Highlight New Quality Productivity Chongqing Fund (弘晖新质生产力重庆基金) on 2025-12-18. The partnership anchors HLC's western-China biomed investment strategy and provides access to the regional biomed industrial cluster.
• Wuxi Huishan District Government (无锡惠山)moderateGTM or Marketing Partner · 1 April 2025HLC co-hosted the "Innovation Sets Sail, Huishan-Shenzhen Connection" Wuxi Huishan (Shenzhen) Tech-Finance Cooperation Salon and HLC Angel Fund project roadshow on 2025-04-02. The partnership supports regional deal sourcing, angel-stage investment promotion, and HLC angel fund deployment in the Yangtze River Delta.
• Huangpu Central Sci-Innovation Zone (黄浦中央科创区)minorGTM or Marketing Partner · 1 November 2024HLC hosted the Huangpu Central Sci-Innovation Zone Innovation Accelerator Camp on 2024-11-25, supporting early-stage company development and regional deal sourcing in Shanghai's Huangpu District.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Hillhouse Capital: Hillhouse is a mega-scale Chinese investment platform with deep healthcare and technology exposure through public and private strategies. It is a much larger incumbent competing for premium Chinese healthcare/tech deals and LP capital alongside HLC.
• HongShan (Sequoia China): HongShan is one of China's largest VC platforms, with broad healthcare and technology exposure across stages and currencies. It is a broader incumbent that competes with HLC on premium Chinese healthcare/tech deals and co-investor allocations.

Regional players

• Vivo Capital: Vivo Capital is a healthcare-focused PE/VC firm primarily operating in the US with growing Asia-Pacific activity, comparable to HLC in vertical focus (healthcare/biotech) but operating from a different geographic base. Useful cross-border healthcare investor comparable.

Emerging players

• OrbiMed: OrbiMed is a global healthcare-dedicated investment firm with significant Asia-Pacific activity, comparable to HLC in its healthcare-vertical focus and stage coverage. Both invest across pharma, devices, and diagnostics globally.

Direct peers

• Legend Capital (君联资本): Legend Capital is a top-tier Chinese VC/PE firm with deep healthcare and technology coverage and RMB+USD funds, directly comparable to HLC's healthcare/tech dual-vertical model. Both target growth-stage Chinese companies and have produced multiple listed healthcare and tech names.
• CBC Group (C-Bridge Capital): CBC Group is a China-focused healthcare investment platform with cross-border capabilities, directly comparable to HLC's healthcare-vertical strategy and RMB+USD fund structure. Both are dedicated healthcare specialists active in Chinese biotech and medtech.
• Loyal Valley Capital: Loyal Valley Capital is a Chinese PE/VC firm with healthcare, technology, and consumer coverage across RMB and USD vehicles, with comparable focus on healthcare innovation and growth-stage Chinese companies to HLC.
• FountainVest Partners: FountainVest is a leading Chinese growth-equity and PE investor with significant healthcare and technology exposure, comparable to HLC in stage focus and sector mix. Both deploy RMB and USD capital into Chinese growth-stage companies.
• Qiming Venture Partners: Qiming is a leading Chinese venture firm with a healthcare and technology focus that closely mirrors HLC's vertical strategy. Both lead multi-stage Chinese investments, participate in global biotech licensing, and maintain RMB+USD fund vehicles; HLC even co-invested in Vivatides Therapeutics' Series A led by Qiming.
• IDG Capital: IDG Capital is a long-tenured Chinese VC with healthcare and technology coverage across RMB and USD vehicles, comparable in stage, vertical mix, and exit profile to HLC. Both have produced multiple Chinese healthcare IPOs and pursue cross-border investment activity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments180 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Highlight Capital